Sustained plasma TNF-α and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans

AIDS

Volumn 13, Issue 16, 1999, Pages 2231-2237

  Lawn, Stephen D ^a,b   Shattock, Robin J ^b   Acheampong, Joseph W ^c   Lal, Renu B ^a   Folks, Thomas M ^a   Griffin, George E ^b   Butera, Salvatore T ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

Author keywords

Africa; HIV 1 load; Immune activation; Opportunistic infection; Tuberculosis; Tumour necrosis factor

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; HLA DR ANTIGEN; INTERLEUKIN 6; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AFRICA; ARTICLE; ASSAY; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GHANA; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; LUNG TUBERCULOSIS; MALE; PRIORITY JOURNAL; VIRUS ENVELOPE; VIRUS LOAD; VIRUS REPLICATION;

EID: 0032711787     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199911120-00005     Document Type: Article

References (40)

1. 1. Msamanga GI, Fawzi WW. The double burden of HIV infection and tuberculosis in sub-Saharan Africa. New Engl J Med 1997, 337:849-851.
2. 2. Nelson AM, Perriens JH, Kapita B, et al. A clinical and pathological comparison of the WHO and CDC case definitions for AIDS in Kinshasa, Zaire: is passive surveillance valid? AIDS 1993, 7:1241-1245.
3. 3. Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a west African city. AIDS 1993, 12:1569-1579.
4. 4. Kassim S, Sassan-Mokoro M, Ackah A, et al. Two year follow-up of persons with HIV-1 and HIV-2 associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995, 9:1185-1191.
5. 5. Small PM, Schecter GF, Goodman PC, et al. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. New Engl J Med 1991, 324:289-294.
6. 6. Nunn P, Brindle R, Carpenter L, et al. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Am Rev Respir Dis 1992, 146:849-854.
7. 7. Whalen C, Horsbrough CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of HIV infection after tuberculosis. Am J Respir Crit Care Med 1995, 151:129-135.
8. 8. Lederman MM, Georges DI, Kusner DJ, Mudido P, Giam C-Z, Toossi Z. Mycobacterium tuberculosis and its purified protein derivative activate expression of human immunodeficiencey virus. J Acquir Immune Def Syndr 1991, 7:727-733.
9. 9. Shattock RJ, Friedland JS, Griffin GE. Phagocytosis of M. tuberculosis modulates human immunodeficiency virus replication in human moncytic cells. Res Virol 1994, 75:849-856.
10. 10. Zhang Y, Nakata K, Weiden M, Rom W. Mycobacterium tuberculosis enhances HIV-1 replication by transcriptional activation at the long terminal repeat. J Clin Invest 1995, 95:2324-2331.
11. 11. Garrait V, Cadranel J, Esvant H, et al. Tuberculosis generates a microenvironment enhancing the productive infection of local lymphocytes by HIV. J Immunol 1997, 159:2824-2830.
12. 12. Nakata K, Rom W, Honda Y, et al. M. tuberculosis enhances HIV-1 replication in the lung. Am J Respir Crit Care Med 1997, 155:996-1003.
13. 13. Vanham G, Edmonds K, Qing L, et al. Generalised immune activation in pulmonary tuberculosis: coactivation with HIV infection. Clin Exp Immunol 1996, 103:30-34.
14. 14. Wallis RS, Helfand MS, Whalen CC, et al. Immune activation, allergic drug toxicity and mortality in HIV-positive tuberculosis. Tuber Lung Dis 1996, 77:516-523.
15. 15. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996, 157:1271-1278.
16. 16. Nkengasong JN, Kalou M, Maurice M, et al. Comparison of NuctiSens and Amplicor monitor assays for quantification of human immunodeficiency virus type-1 (HIV-1) RNA in plasma of persons of persons with HIV-1 subtype A infection in Abidjan, Cote D'Ivoire. J Clin Microbiol 1998, 36:2495-2498.
17. 17. Cantin R, Fortin J-F, Tremblay M. The amount of HLA-DR proteins acquired by HIV-1 is virus strain and cell type-specific. Virology 1996, 218:372-381.
18. 18. Wallis RS, Nsubuga P, Whalen C, et al. Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial. J Infect Dis 1996, 174:727-733.
19. 19. Morris L, Martin DJ, Sacks L, et al. Persistent elevation of HIV viral load during therapy for tuberculosis. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 259].
20. 20. Gilks CF, Brindle RJ, Otieno LS, et al. Extrapulmonary and disseminated tuberculosis in HIV-1 seropositive patients presenting to the acute medical services in Nairobi. AIDS 1990, 4:981-985.
21. 21. Poli G, Bressler P, Kinter A, et al. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor α by transcriptional and post-transcriptional mechanisms. J Exp Med 1990, 172:151-158.
22. 22. Bekker LG, Maartens G, Steyn L, Kaplan G. Selective increase in plasma tumor necrosis factor alpha and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis. J Infect Dis 1998, 178:580-584.
23. 23. Tremblay MJ, Forlin J-F, Cantin R. The acquisition of host-encoded proteins by nascent HIV-1. Immunol Today 1993, 19:346-351.
24. 24. Bastiani L, Laal S, Kim M, Zolla-Pazner S. Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions. J Virol 1997, 71:3444-3450.
25. 25. Saarloos M-N, Sullivan BL, Czerniewski MA, Parameswar KD, Spear GT. Detection of HLA-DR associated with monocytotropic, primary, and plasma isolates of human immunodeficiency virus type 1. J Virol 1997, 71:1640-1643.
26. 26. Law K, Weiden M, Harkin T, Tchou-Wong K, Chi C, Rom WN. Increased release of interleukin-1 beta, interleukin-6, and TNF-α by bronchoalveolar cells lavaged from involved sites in pulmonary tuberculosis. Am J Respir Crit Care Med 1996, 153:799-804.
27. 27. Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIV during opportunistic infections. Science 1997, 276:1857-1861.
28. 2-microglobulin in HIV-1-associated tuberculosis. J Infect Dis 1993, 167:43-48.
29. 29. Li Q, Gebhard K, Schaker T, et al. The relationship between tumor necrosis factor and human immunodeficiency virus gene expression in lymphoid tissue. J Virol 1997, 71:7080-7082.
30. 30. Beutler B, Cerami A. The common mediator of shock, cachexia and tumor necrosis. Adv Immunol 1988, 42:213-231.
31. 31. Von Sydow M, Sonnerborg A, Gaines H, Strannegard O. Interferon-alpha and tumor necrosis factor alpha in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses 1991, 7:375-380.
32. 32. Bentwich Z, Kalinkovich A, Weisman Z. Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today 1995, 16:187-191.
33. 33. Blanchard A, Montagnier L, Gougeon M-L. Influence of microbial infections on the progression of HIV disease. Trends Microbiol 1997, 5:326-331.
34. 34. Rizzardini C, Piconi S, Ruzzante S, et al. Immunological activation markers in the serum of African and European HIV-positive and seronegative individuals. AIDS 1996, 10:1535-1542.
35. 35. Ayehunie S, Sonnerborg A, Yemane-Berhan T, Zewdie DW, Britton S, Strannegard O. Raised levels of tumour necrosis factor-alpha and neopterin, but not interferon-alpha, in serum of HIV-1-infected patients from Ethiopia. Clin Exp Immunol 1993, 91:37-42.
36. 36. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. New Engl J Med 1996, 334: 1222-1230.
37. 37. Sulkowski MS, Chaisson RE, Karp CL, Moore RD, Margolick JB, Quinn TC. The effect of acute infectious illnesses on plasma human immunodeficiency virus type I load and the expression of serologic markers of immune activation among HIV-infected adults. J Infect Dis 1998, 178:1642-1648.
38. 38. Huffman IF, Jere CS, Taylor TE, et al. The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS 1999, 13:487-494.
39. 39. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J AIDS Hum Retroviruses 1996, 11:247-257.
40. 40. Pape JW, Simone SS, Ho JL, Hafner A, Johnson WD. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993, 342:268-372.